Department of Cardiology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China; Heart Failure Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Ann Palliat Med. 2021 May;10(5):5455-5461. doi: 10.21037/apm-21-877. Epub 2021 May 19.
To analyze the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
Patients were divided into a control group (bisoprolol), with 39 cases, and a combination group (bisoprolol combined with sacubitril valsartan sodium tablets), with 42 cases, according to their different medications after surgery. The 6-min walking test distance, heart rate, oxygen saturation, serological indicators, cardiac function, incidence of cardiac adverse events, and adverse reactions of patients were compared between the 2 groups after treatment.
The 6-min walking distance of the combination group was significantly higher than that of the control group, the heart rate was lower than that of the control group (P<0.05), and there was no difference in oxygen saturation (P>0.05). The levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), intercellular adhesion molecule-1 (ICAM-1), and aldosterone (ALD) after treatment in the combination group were significantly lower than those in the control group (P<0.05). After treatment, the left ventricular end diastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD) of the combination group were significantly lower than those of the control group, and the left ventricular ejection fraction (LVEF) was significantly higher (P<0.05). There was no difference in left ventricular posterior wall thickness (LVPWT) level (P>0.05). The proportion of normal diastolic function in the combination group was 78.57%, which was significantly higher than 43.59% in the control group, and the proportion of grade II was significantly lower than that in the control group (4.76% vs. 25.64%) (P<0.05). The total incidence of adverse cardiac events 6 months after treatment in the combination group was 9.52%, which was significantly lower than 25.364% in the control group (P<0.05). There were no deaths in the 2 groups, and there was no difference in adverse reactions (P>0.05).
Bisoprolol combined with sacubitril valsartan sodium tablets has a good application effect in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after PCI. It can promote cardiac rehabilitation and improve cardiac function, and reduce the incidence of cardiac adverse events.
分析比索洛尔联合沙库巴曲缬沙坦钠片在经皮冠状动脉介入治疗（PCI）后急性心肌梗死合并左心衰竭患者心脏康复中的应用效果。
根据术后不同用药将患者分为对照组（比索洛尔）39 例和联合组（比索洛尔联合沙库巴曲缬沙坦钠片）42 例。比较两组患者治疗后的 6 分钟步行试验距离、心率、血氧饱和度、血清学指标、心功能、心脏不良事件发生率及不良反应。
联合组 6 分钟步行距离明显高于对照组，心率低于对照组（P<0.05），血氧饱和度无差异（P>0.05）。联合组治疗后 N 末端脑钠肽前体（NT-proBNP）、细胞间黏附分子-1（ICAM-1）和醛固酮（ALD）水平明显低于对照组（P<0.05）。治疗后联合组左心室舒张末期直径（LVEDD）和左心室收缩末期直径（LVESD）明显低于对照组，左心室射血分数（LVEF）明显高于对照组（P<0.05）。左心室后壁厚度（LVPWT）水平无差异（P>0.05）。联合组正常舒张功能比例为 78.57%，明显高于对照组的 43.59%，二级比例明显低于对照组（4.76%比 25.64%）（P<0.05）。联合组治疗 6 个月后心脏不良事件总发生率为 9.52%，明显低于对照组的 25.364%（P<0.05）。两组均无死亡病例，不良反应无差异（P>0.05）。
比索洛尔联合沙库巴曲缬沙坦钠片在 PCI 后急性心肌梗死合并左心衰竭患者心脏康复中应用效果较好，能促进心脏康复，改善心功能，降低心脏不良事件发生率。
